# OnCo record sacituzumab-govitecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sacituzumab-govitecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sacituzumab-govitecan" ;
  schema:name "Sacituzumab govitecan"@en ;
  schema:description "The first TROP2-targeted ADC. It delivers a strong chemotherapy directly to breast and bladder cancer cells and is now a first-line option in triple-negative breast cancer."@en ;
  schema:url <https://onco.cc/drugs/sacituzumab-govitecan/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sacituzumab_govitecan> ;
  owl:sameAs <http://www.wikidata.org/entity/Q23901469> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sacituzumab%20govitecan>, <https://www.nice.org.uk/guidance/ta819>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22TRODELVY%22>, <https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Trodelvy" ;
  onco:approval "US 2020: Metastatic TNBC, ≥2 prior lines (accelerated; full 2021)", "US 2023: HR+/HER2- metastatic breast cancer after endocrine therapy and ≥2 chemotherapies", "US 2026: First-line metastatic TNBC: monotherapy (PD-1 ineligible) or with pembrolizumab (PD-L1 CPS ≥10)", "EU 2021: mTNBC ≥2 lines; HR+ 2023", "EU 2021: Unresectable or metastatic TNBC after two or more systemic therapies, at least one for advanced disease (ASCENT); marketing authorisation issued 22 November 2021", "EU 2026: First-line unresectable locally advanced or metastatic TNBC in patients who are not candidates for PD-1 or PD-L1 inhibitor therapy (ASCENT-03); listed in the EMA therapeutic indications read on 24 September 2026", "UK 2022: Unresectable triple-negative locally advanced or metastatic breast cancer after two or more systemic therapies, at least one for advanced disease; NICE TA819 (17 August 2022) recommends within the marketing authorisation with a commercial arrangement" ;
  onco:acceleratedApproval "US 2020-04-22: Adults with metastatic TNBC following at least 2 prior therapies for metastatic disease", "US 2021-04-13: Treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor" ;
  onco:acceleratedApprovalConfirmed "US 2021-04-07: Adults with metastatic TNBC following at least 2 prior therapies for metastatic disease" ;
  onco:related <https://onco.cc/biomarkers/pd-l1-cps/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/trop2/> ;
  onco:companies <https://onco.cc/companies/gilead/> ;
  onco:terms <https://onco.cc/terms/bystander-effect/>, <https://onco.cc/terms/payload/>, <https://onco.cc/terms/cl2a/> ;
  onco:trials <https://onco.cc/trials/ascent/>, <https://onco.cc/trials/ascent-03/>, <https://onco.cc/trials/ascent-04/>, <https://onco.cc/trials/nct05089734/>, <https://onco.cc/trials/nct06801834/>, <https://onco.cc/trials/nct06486441/>, <https://onco.cc/trials/nct05633667/>, <https://onco.cc/trials/nct05186974/>, <https://onco.cc/trials/nct06926920/>, <https://onco.cc/trials/nct03547973/>, <https://onco.cc/trials/nct05840211/>, <https://onco.cc/trials/nct05119907/>, <https://onco.cc/trials/nct05609968/>, <https://onco.cc/trials/nct05101096/>, <https://onco.cc/trials/nct04454437/>, <https://onco.cc/trials/nct03964727/>, <https://onco.cc/trials/nct04639986/>, <https://onco.cc/trials/nct05327530/>, <https://onco.cc/trials/nct06827613/>, <https://onco.cc/trials/diamond/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-keynote-355-nejm-2022/> .